Ivax Paxene Second-Line Indication Reflects Comparison To Doxil/DaunoXome
The second-line Kaposi's sarcoma indication for Ivax' paclitaxel brand Paxene in the European Union appears to be based on a balancing of potentially superior response rates against a potentially greater risk of neutropenia, the European Public Assessment Report indicates.
You may also be interested in...
The public dissemination of safety data from Phase I and Phase II trials of Bristol-Myers Squibb's Taxol (paclitaxel) render the company's three-hour infusion patent for the oncologic drug "obvious," a U.K. patent court has ruled.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials